Mpox (monkeypox) pathfinder

You can keep up to date on the latest WA Communicable Disease Control information by subscribing to one or more of their distribution lists: Vaccine updates (general); Virus WAtch; NSP News; and Infectious Diseases Health Alerts.

Information on WA DoH's mpox immunistation program. Covers vaccine eligibility, clinical guidance, reporting & notification requirements, and vaccine ordering.

This summary covers the epidemiology, diagnosis, management and follow up treatment for mpox. Includes coverage of vaccines and therapeutics.

This topic reviews the treatment and prevention of mpox. Contains a section covering antiviral therapy.

This topic will address the virology of vaccinia virus, available vaccines, vaccination procedures, contraindications, and adverse events.

Tecovirimat is an oral antiviral therapy approved in Canada for the treatment of human smallpox disease in adult and pediatric patients weighing at least 13 kg. While tecovirimat is only approved for the treatment of smallpox, CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from tecovirimat for the treatment of human monkeypox infection. | CADTH (Candian Agency for Drugs and Technologies.

Authors' conclusions: Randomized controlled trials review - This review found no evidence from randomized controlled trials concerning the efficacy and safety of therapeutics in humans with mpox.
Authors’ conclusions: Non‐randomized studies review - Very low‐certainty evidence from non‐randomized studies indicates no serious safety signals emerging for the use of tecovirimat in people with mpox infection. In contrast, very low‐certainty evidence raises a safety signal that brincidofovir may cause liver injury. This is also suggested by indirect evidence from brincidofovir use in smallpox. This warrants further investigation and monitoring.

ATAGI (Australian Technical Advisory Group on Immunisation)

Information about mpox (previously known as monkeypox) disease, vaccines and recommendations for vaccination.

Guidelines for health professionals that outline the therapeutic options for the management of human Monkeypox virus infection and vaccine related complications.

SAGE's (Strategic Advisory Group of Experts on Immunization) current position paper is concerned with vaccines and vaccination against mpox and smallpox and includes off-label recommendations. For the latest SAGE updates/alerts go to: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization. PLEASE NOTE: This document replaces the 2022 interim guidance on mpox vaccination and the 2014 meeting report on smallpox vaccines and smallpox vaccination.

World Health Organization (WHO) has announced the MVA-BN (Modified vaccinia Ankara-Bavarian Nordic) vaccine as the first vaccine against mpox to be added to its prequalification list 13/9/2024.

Information in this document provides additional details on shipment, storage temperatures, shelf-life, and supportive temperature excursion information to support distributors and end-users with necessary information and instructions to use the product in a safe and effective manner. | PHAC (Public Health Agency of Canada).

Information regarding UKHSA's vaccine strategy in response to the UK mpox outbreak.

Recommendations for the use of pre- and post-exposure vaccination during an mpox incident.

Advice to help lower the chance of passing mpox infection to others during post-exposure vaccination clinics.

Guidance for public health professionals on smallpox and mpox immunisation.

BHIVA's (British HIV Association) rapid guidance on the safety and efficacy of mpox vaccines and therapeutics for people with HIV who have contracted mpox.

SEE: 6. Antivirals and other therapies (1 recommendation)

While there is not yet sufficient evidence to inform clinical management guidelines, WHO has developed the emergency use protocol for tecovirimat for mpox under the MEURI (Monitored Emergency Use of Unregistered and Experimental Interventions) framework.
NB: Please scroll down the screen to view the protocol.

BHIVA's (British HIV Association) rapid guidance on the safety and efficacy of mpox vaccines and therapeutics for people with HIV who have contracted mpox.

ATAGI information on the MPX vaccines available - JYNNEOS® and ACAM2000™ - and who they are recommended for.

Fact sheet provides key information for consumers and health professionals about using JYNNEOS® vaccine to protect against mpox (monkeypox).

This list of FAQs is designed for consumers.

This factsheet is given to a person who has been identified as someone who may have mpox (formerly known as monkeypox) and who is awaiting their mpox test results.

This paper outlines relevant information about the mpox vaccine. It shows how there is a limited supply of these vaccinations available to the community, which has led to logistical and social challenges. This paper describes several strategies to address these challenges such as tailoring outreach to communities, delaying access to second doses and delivering the vaccination intradermally. | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

A consumer factsheet on mpox vaccines and where to get vaccinated. Emen8 is an Australian online sexual health and wellbeing initiative for gay, bisexual, and other men (cis and trans) who have sex with men.

Applies to England | Information for consumers on the smallpox vaccination - Modified Vaccinia Ankara (MVA) - used to protect against the monkeypox virus (MPXV). Contents includes: Who is MVA recommended for; Using MVA in children; People who cannot receive the MVA vaccine; People who may be better to delay vaccination; Others that need to take special care; If you are pregnant; Breastfeeding and the vaccine; If you are taking other medicines; and Side effects of MVA vaccine.

Applies to England | Information for consumers on the Intradermal mpox vaccination that has been endorsed by the UK’s Joint Committee on Vaccination and Immunisation (JCVI) and is also now being used in the US.

An overview of Tecovirimat SIGA and why it is authorised in the EU. | EMA (European Medicines Agency).